369
Participants
Start Date
May 31, 2007
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
SYR-472
SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472
SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472
SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472
SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Placebo
SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Birmingham
Mobile
Montgomery
Pell City
Tallassee
Sierra Vista
Fountain Valley
Los Angeles
National City
Pismo Beach
Clearwater
North Miami Beach
Ocoee
Orlando
Plantation
Dawsonville
Gainesville
Naperville
Elkhart
Indianapolis
Slidell
Taunton
Ann Arbor
Great Falls
Scottsbluff
Las Vegas
Brooklyn
Charlotte
Shelby
Sparta
Fargo
Bensalem
Dayton
Kettering
Central Point
Altoona
Providence
Clemson
Columbia
Greer
Rapid City
Cleveland
Kingsport
Arlington
Fort Worth
North Richland Hills
San Antonio
Spring
Sugarland
Hampton
Richmond
Santiago
Temuco
Ostrava
Prague
Guatemala City
Quetzaltenango
Eger
Szentes
Riga
Sigulda
Valmiera
Kaunas
Kėdainiai
Klaipėda
Vilnius
Ponce
Alba Iulia
Baia Mare
Bihor
Brasov
Bucharest
Constanța
Ploieşti
Satu Mare
Târgovişte
Kemerovo
Moscow
Saint Petersburg
Ufa
Volgograd
Yaroslavl
Banská Bystrica
Bratislava
Prešov
Kharkiv
Vinnytsia
Lead Sponsor
Takeda
INDUSTRY